CLARUS THERAPEUTICS HOLDINGS (CRXT)

US18271L1070 - Common Stock

0.099  -0.06 (-36.94%)

After market: 0.101 +0 (+2.02%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CLARUS THERAPEUTICS HOLDINGS

NASDAQ:CRXT (8/30/2022, 7:05:42 PM)

After market: 0.101 +0 (+2.02%)

0.099

-0.06 (-36.94%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap5.15M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CRXT Daily chart

Company Profile

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is headquartered in Northbrook, Illinois and currently employs 16 full-time employees. The company went IPO on 2020-12-17. The firm is focused on the commercialization of JATENZO, an oral T-replacement, or T-replacement therapy (TRT). The Company’s lead product, JATENZO, an androgen indicated for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. In addition, JATENZO focuses on the classic signs and symptoms associated with hypogonadism, including psychosexual symptoms, body mass index, fat mass and bone mineral density. The firm plans to focused on the development and commercialization of T and metabolic therapies for men and women.

Company Info

CLARUS THERAPEUTICS HOLDINGS

555 Skokie Boulevard, Suite 340

Northbrook ILLINOIS

P: 16463030737.0

CEO: Joseph Hernandez

Employees: 16

Website: https://clarustherapeutics.com/

CRXT News

News Imagea year ago - Clarus Therapeutics Holdings, Inc.Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder

Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE...

News Imagea year ago - Clarus Therapeutics Holdings, Inc.Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder
News Image2 years ago - Clarus Therapeutics Holdings, Inc.Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-III) projected to conclude late October 2022...

News Image2 years ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news on Tuesday morning.

News Image2 years ago - InvestorPlaceWhy Is Pinduoduo (PDD) Stock Up 18% Today?

Pinduoduo (PDD) stock is getting a boost on Monday after the Chinese agriculture tech company released results for Q2 2022.

News Image2 years ago - InvestorPlaceDear AMC Stock Fans, Mark Your Calendars for Sept. 3

Fans of AMC Entertainment (AMC) stock will want to keep an eye on the company come Sept. 3 as it prepares for a special theater event.

CRXT Twits

Here you can normally see the latest stock twits on CRXT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example